Net sales for the consolidated fiscal year ended March 31, 2025, amounted to 119,010 million yen (up 13.6% year on year). Operating income was 22,067 million yen (up 21.2% year on year), and ordinary income was 21,577 million yen (up 24.6% year on year). Profit attributable to owners of the parent was 10,780 million yen (up 24.6% year on year), which reflects impairment losses recognized by Taiyo Pharma Co., Ltd. following a review of sales rights with declining profitability.

 

Results by segment were as follows.
The Group consists of segments based on operating subsidiaries and comprises two reportable segments: the Electronics business and the Medical and Pharmaceuticals business.

 

Electronics
Due to increased sales volumes of rigid and PKG products and the depreciation of the yen, net sales in the Electronics totaled 81,703 million yen (up 14.4% year on year), an increase of 10,287 million yen from the previous fiscal year. Operating income was 21,458 million yen (up 30.4%), an increase of 5,002 million yen year on year.
During the period under review, the average exchange rate was 152.5 JPY per USD, representing a depreciation of 8.1 yen compared to the previous period’s average rate of 144.4 JPY per USD.

Electronics

＜Reasons for the Increase in Net Sales＞
 

  • Rigid products
    Sales volume for products below increased:
    • Automotive-related products in China
    • Smartphone-related products
    • Dry film materials for display-related products
       
  • PKG products
    • Sales volume increased, particularly for memory products, due to the recovery in demand
       
  • The depreciation of the yen had a positive impact on our performance

Medical and Pharmaceuticals
Due to the conversion of Ricc Co., Ltd. (currently mystarz Co., Ltd.) into a consolidated subsidiary, increased demand in the manufacturing and marketing business, and higher contract volumes in the contract manufacturing business, net sales in the Medical and Pharmaceuticala totaled 31,558 million yen (up 7.8% year on year), an increase of 2,288 million yen from the previous fiscal year. Operating income was 2,049 million yen (down 36.9%), a decrease of 1,199 million yen year on year.

Medical and Pharmaceuticals

＜Reasons for the Increase in Net Sales＞
 

  •  Ricc Co., Ltd. (currently mystarz Co., Ltd.)
    • It has been converted into our consolidated subsidiary
       
  •  Taiyo Pharma Co., Ltd. (manufacturing and marketing of pharmaceuticals)
    • There was an increase in demand for drugs with the same indications, which were in short supply from other companies, as well as for cough suppressants and expectorants
    • The approval for manufacturing and marketing of “REMINYL®,” therapeutic agent for Alzheimer's disease, has been transferred to Taiyo Pharma
       
  • Taiyo Pharma Tech Co., Ltd. (CDMO)
    • Contract volume increased due to an increase in demand from manufacturing customers

(Unit: millions of yen)

Item

FY2024

FY2025

Change

Percentage Change

Net Sales

104,775

  119,010

 14,235

 14%

Operating Income

18,203

  22,067

 3,864

 21%

Ordinary Income

17,310

  21,577

 4,267

 25%

Profit attributable to owners of parent

8,654

  10,780

 2,126

 25%